Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doxorubicin microneedle array - SkinJect

Next Previous
Drug Profile

Doxorubicin microneedle array - SkinJect

Alternative Names: D-MNA; Doxorubicin-containing MNA - SkinJect; SkinJect™

Latest Information Update: 14 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator SkinJect
  • Class Anthracyclines; Antineoplastics; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Basal cell cancer

Most Recent Events

  • 06 Mar 2025 Efficacy and adverse event data from phase II trial in Basal cell cancer released by Medicus Pharmaceuticals
  • 27 Feb 2025 Medicus Pharma plans a phase II trial (SKNJCT-004) for Basal cell cancer in United Arab Emirates (UAE)
  • 02 Dec 2024 Medicus plans a Type C meeting with the US FDA to formally discuss the product development and gain further alignment on the clinical pathway in Q2 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top